Document is current
Any future updates will be listed below
-
Authors
Göbel, Kerstin
Pankratz, Susann
Asaridou, Chloi-Magdalini
Herrmann, Alexander M.
Bittner, Stefan
Merker, Monika
Ruck, Tobias
Glumm, Sarah
Langhauser, Friederike
Kraft, Peter
Krug, Thorsten F.
Breuer, Johanna
Herold, Martin
Gross, Catharina C.
Beckmann, Denise
Korb-Pap, Adelheid
Schuhmann, Michael K.
Kuerten, Stefanie
Mitroulis, Ioannis
Ruppert, Clemens
Nolte, Marc W.
Panousis, Con
Klotz, Luisa
Kehrel, Beate
Korn, Thomas
Langer, Harald F.
Pap, Thomas
Nieswandt, Bernhard
Wiendl, Heinz
Chavakis, Triantafyllos
Kleinschnitz, Christoph
Meuth, Sven G.
- License Information
-
More Information
Article History
Received: 8 July 2014
Accepted: 14 April 2016
First Online: 18 May 2016
Competing interests
: M.W.N. is an employee of CSL Behring GmbH and owns employee shares in CSL Limited. C.P. is an employee of CSL Limited and owns employee shares in CSL Limited. K.G., M.W.N., C.K. and S.G.M. hold a patent to treat neuroinflammatory disorders with FXIIa inhibitors. The remaining authors declare no competing financial interests.
